The FDA has approved Kanjinti for all approved indications of the reference product Herceptin to treat HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal
The post FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti appeared first on Pharmaceutical Business review.
Original Article: FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti